Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

“For the first time, Indian patients now have access to lasting remission of relapsed and refractory Non-Hodgkin Lymphoma, offering hope to patients when conventional therapies fall shor ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Patients who participate in a clinical trial ... and 64 percent for stage 4 non-Hodgkin lymphoma. Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined ...

She and her colleagues found that patients with non-Hodgkin lymphoma who had poor physical function prior to undergoing CAR T-cell therapy had an increased one-year mortality risk and a greater ...

Tea planter Vishal Mahindra was twice diagnosed with non-Hodgkin's lymphoma, a type of blood cancer that develops in the ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...